Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada, its developer, Amylyx Pharmaceuticals, announced. Its market availability comes about 1.5 months after the therapy was conditionally approved by Health Canada for this neurodegenerative disease. The regulatory decision was based on…
News
TDP-43 protein abnormalities characteristic of most amyotrophic lateral sclerosis (ALS) cases contribute to the loss of motor neurons mostly by limiting the function of a protein called stathmin-2 (STMN2), a study reported. Results indicate that boosting STMN2 levels may be a useful approach in treating ALS, according to its…
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential treatments for amyotrophic lateral sclerosis (ALS). The non-dilutive funds became available following the company’s acquisition of Alpha-5 Integrin, the preclinical biotech company that originally developed the experimental antibodies for…
Amylyx Pharmaceuticals has partnered with Sunnybrook Research Institute (SRI) to find new therapeutic candidates for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Under terms of the two-year sponsored research agreement, SRI will work to identify potential therapeutics that potently and specifically inhibit Bax and Bak, two proteins…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Biogen for approval of the company’s experimental therapy tofersen to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The FDA has granted the application accelerated review and a decision…
The National Institutes of Health (NIH) has awarded $2.3 million to advance into testing an app that could improve how amyotrophic lateral sclerosis (ALS) is diagnosed, track the disease’s progression, and help assess a treatment’s effectiveness. The three-year Small Business Technology Transfer (STTR) grant was awarded to Modality.AI and…
Tara Gottlieb lost her father to amyotrophic lateral sclerosis (ALS) in November, but the Massachusetts resident said she’s only just begun advocating for people with the disease and working to help find a cure. Gottlieb remembers her father, David Gottlieb, as a generous, selfless, caring man. She and her brother,…
Orphan drug status has been recommended in the EU for Clene Nanomedicine’s CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS), by a committee of the European Medicines Agency (EMA). CNM-Au8 is emerging as a promising treatment for the progressive neurodegenerative condition, with…
A viral protein called HERV-K ENV is often detectable in the fluid around the brains of people with amyotrophic lateral sclerosis (ALS), and is toxic to nerve cells, a new study shows. However, blocking this protein with GeNeuro‘s experimental antibody GNK301 reduced those toxic effects in cell…
The first patient has been dosed in an open-label Phase 2 trial that’s evaluating Seelos Therapeutics’ experimental therapy SLS-005 in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases associated with the accumulation of toxic protein aggregates. Called a basket trial because it tests one therapy in…
Recent Posts
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’
- Higher blood lactate levels tied to survival, weight changes in ALS
- AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple